| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 30.1 Billion |
| Market Size in 2026 | USD 33.9 Billion |
| Market Size by 2032 | USD 72.5 Billion |
| Projected CAGR | 13.4% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Fragmented |
Explore the market potential with our data-driven report
The esoteric testing market size was USD 30.1 billion for 2025, and it will grow by 13.4% during 2026–2032, to reach USD 72.5 billion by 2032.
The market growth is driven by the rising prevalence of chronic, infectious, and genetic diseases, as well as the increasing geriatric population. According to the World Health Organization (WHO), non-communicable diseases account for approximately 74% of global deaths annually, significantly increasing the demand for advanced diagnostic testing, particularly in oncology, endocrinology, and immunology. Additionally, the emergence of advanced technologies, such as mass spectrometry and gene sequencing, which enable highly accurate and reliable diagnoses and address unmet diagnostic needs; and the increase in test volumes per patient are driving the expansion of the global market.
Moreover, an increase in the demand for early disease diagnosis using specialized tests; growth in the utilization of advanced DNA sequencing technologies in precision medicine, the awareness of which continues to rise; and an increase in funding and research grants for the development of novel esoteric tests lead to market expansion. The Brazilian Ministry of Health's National Policy for Comprehensive Care for People with Rare Diseases, implemented through the Unified Health System (SUS), has expanded access to specialized diagnostic and genetic testing services through dedicated rare disease care networks. The integration of artificial intelligence and machine learning is further improving diagnostic accuracy, as accurate and cost-effective diagnosis remains a major challenge for healthcare systems globally.
A defining trend reshaping the esoteric testing market is the shift from single-analyte assays toward multiplexed, sequencing-based panels capable of evaluating dozens of biomarkers from a single specimen. Laboratories are increasingly replacing serial immunoassay and PCR workflows with next-generation sequencing (NGS) platforms that consolidate genetic, oncology, and infectious disease testing into unified workflows, reducing specimen requirements and turnaround time for complex diagnoses.
According to the National Human Genome Research Institute, the cost of sequencing a human genome has fallen from approximately USD 95 million in 2001 to around USD 500 in recent years, a decline that has made routine clinical deployment of multiplex genomic panels commercially viable for reference and hospital laboratories alike. This cost compression is enabling independent and reference laboratories to expand test menus without proportional increases in per-test pricing, while encouraging hospital-based laboratories to bring previously outsourced genomic testing in-house. As sequencing costs continue to decline, multiplex and panel-based testing is expected to increasingly replace a growing share of single-analyte esoteric assays through the forecast period.
Escalating global cancer incidence, along with the rising burden of chronic and rare diseases, is structurally driving demand for esoteric testing capacity. As disease complexity increases, conventional clinical chemistry and routine pathology are becoming insufficient to accurately characterize tumor biology, genetic risk, and rare autoimmune and metabolic conditions, prompting clinicians to increasingly adopt specialized biomarker, molecular, and genomic panels. According to the International Diabetes Federation, approximately 5.0 million adults in Italy were living with diabetes in 2024, which is significantly increasing demand for endocrinology, metabolic monitoring, and advanced biomarker testing services.
According to the International Agency for Research on Cancer, there were approximately 20 million new cancer cases globally in 2022, a figure projected to reach 35 million by 2050, underscoring a rapidly intensifying global cancer burden. This growing burden is directly translating into higher per-capita test ordering rates for oncology and genetic biomarker panels, as treatment protocols increasingly require molecular confirmation before initiating targeted therapies. As cancer incidence continues to rise toward 2050, demand for esoteric oncology and genetic testing capacity is expected to intensify, sustaining strong growth in laboratory test volumes over the forecast period.
A persistent restraint on esoteric testing market growth is the shortage of qualified laboratory personnel required to operate increasingly complex molecular and genomic testing platforms. Specialized disciplines such as cytogenetics, flow cytometry, and anatomic pathology require extended training periods, creating a structural bottleneck that limits how quickly laboratories can scale testing capacity even as demand accelerates.
According to the American Society for Clinical Pathology 2024 Vacancy Survey, anatomic pathology departments reported one of the highest vacancy rates among laboratory disciplines at approximately 28.5%, with hiring timelines for specialized roles frequently extending beyond six months. This workforce shortage is prompting laboratories to increasingly adopt automation and AI-assisted workflow tools to offset staffing gaps and improve operational efficiency. However, despite these advancements, workforce constraints continue to impact testing capacity and turnaround times for complex esoteric panels. In the absence of significant expansion in laboratory training pipelines, workforce shortages are expected to remain a key constraint on capacity growth over the forecast period.
Expanding regulatory acceptance of self-collected specimens is opening a new growth pathway for esoteric testing providers seeking to reach patients who forgo screening due to access or convenience barriers. Historically, esoteric testing has required clinician-collected specimens processed through centralized laboratories, limiting reach in underserved and rural populations. According to the U.S. Food and Drug Administration, the agency authorized the expanded use of self-collected specimens for certain HPV testing workflows in 2024, establishing a regulatory pathway that diagnostics providers are now extending toward other screening applications.
According to the World Health Organization, the global target is to achieve 70% cervical cancer screening coverage, highlighting a significant gap in current screening levels and a large underserved population. The integration of telehealth consultations with mailed specimen kits is extending esoteric testing access beyond traditional phlebotomy-dependent models. As regulatory frameworks mature and payer reimbursement for self-collected testing expands, decentralized collection models are expected to unlock incremental test volumes from previously underscreened populations.
The oncology testing category holds the largest market share, of 35%, in 2025, commanded by the high diagnostic complexity of cancer biology and the clinical necessity of molecular confirmation before initiating targeted therapy. This leadership is reinforced by the rapid expansion of FDA-cleared companion diagnostic and tumor-profiling assays that pair specific biomarkers with approved therapeutics, driving routine adoption across oncology practices and reference laboratories. The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence reports that it authorized 76 oncology devices in 2024, including 27 in vitro diagnostic devices and two new NGS-based tumor profiling assays with companion diagnostic claims.
The genetic testing category will have the highest CAGR, of approximately 14.0%, due to the advancing genetic testing technologies, growing count of genetic disorder patients, increasing awareness of genetic testing for cancer screening and prenatal screening, and government support for fast and accurate genetic diagnoses.
The test types analyzed in this report are:
The chemiluminescence immunoassay testing category holds the largest market share in 2025, due to its high performance, in terms of precision, efficacy of diagnosis, and ability to detect analytes present in minute quantities. In addition to these factors, the increasing research and development efforts related to the diagnosis of autoimmune and infectious diseases, along with the growing adoption of chemiluminescence immunoassays in clinical diagnostics, are expected to accelerate the category's growth in the future.
The DNA sequencing category will have the highest CAGR, of approximately 13.8%, owing to the rising prevalence of infectious diseases, including hepatitis, dengue, and AIDS, along with neurological disorders and cancer. Along with this, the booming geriatric population and the rising demand for affordable diagnostic testing services will propel the advance of this category. The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence approved new NGS-based tumor profiling assays with companion diagnostic claims in 2024.
The technologies analyzed in this report are:
The independent & reference laboratories category holds the larger market share, of 75%, in 2025, sustained by economies of scale in automation, specimen logistics, and disease-specific test menu breadth that smaller facility types cannot replicate. Their structural advantage is reinforced by the disproportionate concentration of testing volume relative to facility count across the U.S. laboratory landscape. According to the Centers for Disease Control and Prevention, hospital and independent laboratories represent approximately 34% of CLIA-certified laboratories but perform nearly 81% of total clinical testing volume in the United States, with independent laboratories recording the highest per-laboratory test throughput among facility types.
The hospital-based laboratories category will have the higher CAGR, as health systems increasingly in-source complex esoteric testing to reduce turnaround times for critical diagnoses and capture outpatient diagnostic volume shifting away from inpatient settings. According to the Peterson-KFF Health System Tracker, citing data from the American Hospital Association, hospital outpatient visits increased by approximately 31% between 2000 and 2023, reinforcing the shift of diagnostic volume toward hospital-affiliated laboratory infrastructure.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, driven by a dense network of independent and reference laboratories with high-throughput automation, favorable reimbursement coverage for molecular and genetic diagnostics under both public and private insurance frameworks, and early regulatory pathways for laboratory-developed tests. Sustained demand for confirmatory infectious disease panels reinforces regional test volumes. According to the Centers for Disease Control and Prevention (CDC), 37,981 people aged 13 years and older received an HIV diagnosis in the United States in 2022, sustaining demand for confirmatory HIV diagnostics, viral-load monitoring, and other specialized infectious disease testing services across the region's reference laboratory networks.
Furthermore, Canada is showing significant growth in this market due to its advancing healthcare infrastructure, rising number of government initiatives for making diagnostic services accessible and affordable, surging demand for ELISA and RT-PCR tests, and the presence of key players providing the associated assay kits, reagents, and testing equipment.
The U.S. represents the largest country market within North America, accounting for the majority of regional market value in 2025, driven by one of the world’s largest concentrations of independent and reference laboratory capacity, a regulatory framework enabling rapid clinical adoption of laboratory-developed and companion diagnostic tests, and substantial federal investment in genomic research infrastructure.
According to the National Institutes of Health, the All of Us Research Program expanded its research dataset to include data from more than 633,000 participants, with its genomic dataset comprising whole-genome sequences from more than 414,000 participants, strengthening the genomic evidence base supporting clinical test development and precision medicine research.
Asia-Pacific will have the highest CAGR, of approximately 14.3%, driven by the rapid expansion of hospital and reference laboratory infrastructure, rising government investment in genomic and precision-medicine programs, and an aging population that is increasing the burden of chronic and noncommunicable diseases across the region's healthcare systems. According to the World Health Organization Western Pacific Region, more than 245 million people aged 65 years and older live across the region, and this population is projected to double by 2050, increasing the burden of chronic diseases and intensifying demand for specialized biomarker, molecular, and genetic testing services.
India is the fastest-growing country market in the region. Expanding genomic research initiatives and increasing adoption of precision medicine support this position. According to the Genome India Project, India completed whole-genome sequencing of 10,000 individuals from 83 diverse populations in 2025. This sequencing initiative created one of the country's largest genomic reference datasets. This dataset is strengthening the foundation for advanced molecular diagnostics and esoteric testing applications.
China represents the largest country market within Asia-Pacific, supported by large-scale national cancer screening infrastructure, rapidly expanding private and hospital-affiliated reference laboratory networks, and sustained government investment in oncology and genomic diagnostics under the Healthy China 2030 initiative. According to the National Health Commission of China, more than 280 million free cervical cancer screenings had been conducted nationwide by 2024, resulting in the detection of approximately 902,000 cases of cervical cancer and precancerous lesions, highlighting the scale of China's screening infrastructure and reinforcing demand for specialized diagnostic testing services.
The regions and countries analysed in this report are:
The market is fragmented, reflecting the highly specialized nature of testing across oncology, genetic, infectious disease, endocrinology, and toxicology segments. No single provider commands a dominant share, as capital-intensive technologies such as next-generation sequencing and mass spectrometry, along with stringent accreditation requirements including CLIA, CAP, and ISO 15189, favor deep domain expertise over large-scale consolidation.
Major reference laboratory networks, including Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, and Sonic Healthcare Limited, collectively account for a significant share through extensive test menus and high-throughput infrastructure. At the same time, specialized genomic and oncology-focused providers and academic laboratories continue to compete through niche capabilities and advanced bioinformatics. High entry barriers and ongoing innovation are expected to sustain this fragmented structure over the forecast period.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages